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1. Introduction
The need for new perspectives on in 
vivo-like and animal-free approaches 
for chemical and pharmaceutical safety 
assessment is growing both in the area of 
drug development and in risk assessment 
of chemicals Registration, Evaluation, 
Authorisation and Restriction of Chemical 
Substances (REACH).[1]
The main points of criticism regarding 
animal testing are related to not only ethical 
concerns but also the limited transferability 
to human physiology, due to significant dif-
ferences in anatomy, organ structure, organ 
function, metabolism, and DNA-repair. 
As an ethical alternative to animal experi-
ments, cellular organ-on-a-chip models 
represent a promising approach to better 
imitate the complex organization of organs 
and tissues, as they allow for 3D cellular 
organization with microfluidics simulating 
circulation in the body.[2–16]
Microfluidic technology is a valuable tool for realizing more in vitro models capturing 
cellular and organ level responses for rapid and animal-free risk assessment of 
new chemicals and drugs. Microfluidic cell-based devices allow high-throughput 
screening and flexible automation while lowering costs and reagent consumption due 
to their miniaturization. There is a growing need for faster and animal-free approaches 
for drug development and safety assessment of chemicals (Registration, Evaluation, 
Authorisation and Restriction of Chemical Substances, REACH). The work presented 
describes a microfluidic platform for in vivo-like in vitro cell cultivation. It is equipped 
with a wafer-based silicon chip including integrated electrodes and a microcavity. A 
proof-of-concept using different relevant cell models shows its suitability for label-
free assessment of cytotoxic effects. A miniaturized microscope within each module 
monitors cell morphology and proliferation. Electrodes integrated in the microfluidic 
channels allow the noninvasive monitoring of barrier integrity followed by a label-free 
assessment of cytotoxic effects. Each microfluidic cell cultivation module can be 
operated individually or be interconnected in a flexible way. The interconnection of 
the different modules aims at simulation of the whole-body exposure and response 
and can contribute to the replacement of animal testing in risk assessment studies in 
compliance with the 3Rs to replace, reduce, and refine animal experiments.
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Standardized cell-based assays do neither mimic the struc-
tural arrangement of different, sometimes highly specialized, 
cell arrangements within an organ or capture defined cell–cell 
interactions, which are important for physiological cell func-
tion. For example, mechanical stimuli in respiration[17] and 
intestinal peristaltic[6] have a decisive influence on the forma-
tion and regulation of a microphysiological environment.
Organ-on-chip models bring the advantage of reproduc-
tion of these microphysiological conditions in vitro and thus 
differ clearly from standardized cell-based assays, e.g., for 
safety testing described in current Organisation for Economic 
Co-operation and Development (OECD) guidelines.[18–23]
A challenge in the cultivation of complex organ models 
under physiologically relevant conditions is the maintenance of 
their function over a long period of time (days, weeks, months). 
Maintenance of organ models is enabled by microfluidic tech-
niques to allow spatial control over fluids in µm-sized channels. 
Microfluidics can be exploited to enhance the physiological 
relevance of 3D cell models. During the last decade, lab-on-a-
chip devices have been developed and used in various fields of 
life sciences.[3,5,9,14,24–36] Various in vitro models have already 
been combined with microfluidic systems (e.g., skin-on-chip, 
lung-on-chip, liver-on-chip, gut-on-chip, kidney-on-chip, retina-
on-chip, and blood-brain-barrier-on-chip).[2,4,5,7,8,11,12,15,16,37–53] 
A much better mimicry of the human in vivo-like physiology can 
be achieved by merging different organs on chip.[5,10,26,34,54–59]
Microfabrication technologies offer new opportunities in 
the construction of miniaturized cell culture systems and 
their applications.[13,60–64] To improve the analytical capability 
of human organ-on-chip systems, various optical[65] or electro-
chemical biosensors[4,35,66] have been integrated in the devices 
to detect cytotoxic agents. Among the sensing technologies, 
impedance spectroscopy and transepithelial electrical resistance 
(TEER) measurements became the label-free method of choice 
for noninvasive determination of cell barrier integrity.[67–71] 
The need for live-cell imaging during cell cultivation has led 
to the development of systems allowing real-time visualization 
and characterization of cell behavior in parallel. These solu-
tions include customized incubators with inverted fluorescence 
microscopes, compact microscopes that can be placed inside a 
laboratory incubator or completely automated cell culture obser-
vation systems.[72–75] All these solutions require costly and bulky 
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lab equipment and do not allow cultivation and simultaneous 
optical analysis under dynamic flow conditions. The rapid pro-
gress in the development of new micro- and nanotechnologies 
together with more advanced cell culture models led to the devel-
opment of a modular microfluidic platform for (nano)safety and 
(nano)drug efficiency screening.[76] This platform innovatively 
combines a microfluidic cartridge for cell cultivation with a minia-
turized incubator microscope for optical analysis and electrodes 
for impedance measurements to determine cytotoxicity.
2. Results and Discussion
2.1. Setup of the Microfluidic Platform
Before fabricating the microfluidic platform (a microfluidic car-
tridge combined with a miniaturized incubator microscope) a 
computational fluid dynamics (CFD) simulation was performed 
within Comsol Multiphysics to determine the requirements for the 
setup. A 3D advection-diffusion model was created and meshed 
using 2.3 million tetrahedral elements, confirmed to give a mesh-
independent solution. The inlet and outlet channels and the cavity 
region, in which the cell models are cultured, was modeled, as 
shown in the cross-section of the model in Figure 1. Fluid flow 
with a density of 998 kg m−3, dynamic viscosity of 8.9 × 10−4 Pa 
s, and volumetric inflow rate of 100 µL h−1 was predicted before 
simulating the transport of chlorpromazine, a soluble pharma-
ceutical compound (diffusion coefficient of 3.25 × 10−10 m2 s−1).[77] 
The no-slip and zero flux boundary conditions were applied at 
the geometry walls. The normalized concentration, c/co (where 
co is the inlet concentration and c is the local concentration) is 
shown on the surfaces of the cavity (Figure  1), demonstrating 
that the species is transported successfully to the cells within 
700  s of entering the chip. No undesirable flow effects, such as 
fluid recirculation, were observed within the cavity geometry 
that could have disturbed the transport of species to the cells.
To confirm that hydrodynamic forces did not have a det-
rimental effect on the adherence of the cells to the surface 
of the microfluidic cavity or exceeded typical values seen in 
vitro which can indicate adverse impact on cell physiological 
behavior, the shear stress was calculated on the cavity sur-
face using the CFD fluid flow model as shown in Figure  2. 
A peak shear stress of 0.0012 dyn cm−2 (for the study flow rate 
of 100 µL h−1) was observed at the mid-point of the cellular sur-
face, with the variation either side of this caused by the change 
in fluid velocity due to the transition from the entry and exit 
channels to the cavity. CFD results and analytical calculations 
for the shear stress (Equation (6)) showed excellent agreement 
(Figure 2d). The shear stress on the cells is shown to be below 
the critical values to cause adverse impact on cell behavior as 
cell viability with critical values taken as 5  dyn  cm−2 (A549), 
0.33 dyn cm−2 (HepG2), and 2 dyn cm−2 (TH-1)[78–80] and is in 
line with other studies within the field.[81]
2.1.1. Microfluidic Cartridge
The core part of the microfluidic cartridge is a custom-designed 
microfabricated silicon chip. It comprises a microcavity with 
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a volume of ≈2.5  µL (Figure  3a), in which the cells are culti-
vated on a thin transparent membrane made of silicon nitride 
that comprises a regular array of microholes (Figure 3b). With 
these microholes, the microfluidic cartridge can be used as a 
minaturized device for barrier models with dense cell layers 
on the silicon nitride membrane. The principle of the bar-
rier model cultivation on the microhole membrane is similar 
to that of commercially available larger coculture systems, as, 
e.g., the Transwell system. In contrast to cell culture inserts 
used in static cultures, the integrated microfluidic channels 
Figure 1. CFD simulation of fluid flow and species transport through a microfluidic channel. a) Cross-section of the geometry and the normalized concen-
tration of species at the cavity walls after b) 400 s, c) 500 s, d) 600 s, e) 700 s, f) 800 s, and g) 900 s (bottom edge of (b)–(g) is left hand edge of cavity in (a)).
Figure 2. CFD prediction of shear stress in the microfluidic channel cavity at flow rates of 50–500 µL h−1. a) Location along the bottom surface of the 
cavity where shear stress was determined. b) Flow velocity (mm s−1) through the center of the microfluidic cell at a flow rate of 100 µL h−1. c) Predicted 
shear stress in the cavity, where distance on the x-axis refers to the position along the cavity wall in the direction of flow. d) Comparison of the mean 
shear stress predicted using CFD with the average shear stress determined by an analytical equation for calculating shear stress in microfluidic channels.
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Figure 3. Setup of microfluidic cartridge and miniaturized incubator microscope platform. a) SEM image of microcavity with microhole array mem-
brane (1.6 mm x 1.6 mm). b) SEM image of microhole array with hole distance 10 µm. c) Microfluidic cartridge with connected tubing and cables for 
impedance measurement. This cartridge is integrated in the miniaturized incubator microscope. d) Incubator microscope with inserted microfluidic 
cartridge and lid, for bright field imaging and cell cultivation under controlled temperature. e) Schematic illustration of the microfluidic cartridge. The 
electrodes (yellow) are positioned in the two fluidic channels. The electric current flows between the electrodes through the pores in the membrane 
(dashed line). f) Schematics of experimental setup with two platform modules for parallel or serial operation.
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allow for the cultivation of the cells under dynamic flow con-
ditions. Figure  3c shows the assembled microfluidic cartridge 
with the integrated silicon chip. The gold electrodes in the 
microchannels are connected with the impedance measure-
ment setup that detects the impedance spectrum between the 
two channels and through the membrane with the cell layer 
(Figure 3c). An exploded view drawing of the individual compo-
nents of the microfluidic cartridge can be found in Figure S1 in 
the Supporting Information.
2.1.2. Miniaturized Incubator Microscope
The developed miniaturized incubator microscope allows for 
continuous real-time monitoring of cell characteristics, such 
as morphology, cell growth, and cell response in the micro-
fluidic cartridge. The inserted microfluidic cartridge is con-
nected with an adapter for temperature regulation (Figure 3d). 
Components for temperature regulation (Peltier elements, 
Negative temperature coefficient thermistors) and the light 
source for bright-field illumination are integrated in the 
fixation lid on the microfluidic cartridge (Figure  3d). The 
horizontal assembly protruding from the side of the micro-
scope tube comprises illumination components for fluores-
cence imaging. The compact microscope has a field of view 
of 1.4  mm  x  1.05  mm and a magnification of 4.4. With the 
restricted numerical aperture (N.A. = 0.208) of the small objec-
tive lens a point-shaped object fluorescing at a wavelength of 
610 nm will theoretically be depicted with a full width at half 
maximum of 1.5 µm, which is in reasonable accordance with 
the camera pixel size of 1.25 µm.
2.1.3. System Integration of the Microfluidic Platform
Each module of the microfluidic platform comprises a fluidic 
system with valves, tubing, and pumps that is integrated with 
the miniaturized incubator microscope and the microfluidic 
cartridge. Cell suspension, reagents, and cell culture medium 
are delivered to and led away from the silicon microcavity via 
flow channels by means of a syringe pump. During cell cul-
tivation, fresh cell culture medium is constantly delivered 
to the cells in the microcavity. The electrodes for impedance 
measurement are positioned in the two fluidic channels and 
the electric current flows through the pores in the membrane 
(Figure 3e). Each platform module, equipped with an imaging 
module and fluidic components, can be operated indepen-
dently or connected with other platform modules operating 
in parallel or in series. Control of the imaging modules and 
time-lapse imaging is performed by a LabView program. The 
electrodes of both microfluidic modules are connected with the 
LabView-controlled impedance measurement system for par-
allel recording of the impedance data (Figure 3f).
2.2. Nanoparticle Synthesis and Characterization
Silver nanoparticles (Ag-NP), fluorescently labeled silica 
nanoparticles with fluorescein isothiocyanate (FITC) 
(SiO2-FITC-NP), titanium dioxide nanoparticles (TiO2-NP), and 
gold NPs functionalized with polyethylene glycol (PEG)-SH 
MW5000 (Au-PEG-NP) were prepared following well-known 
standard procedures. A summary of the physical and chemical 
characteristics of the NPs used in this study is presented in 
Figure S2 and Table S1 in the Supporting Information.
2.3. In Vitro Studies on the Microfluidic Platform
2.3.1. Cell Characteristics on the Microfluidic Platform
The suitability of a silicon nitride membranes as a surface 
for cell cultivation has been demonstrated previously.[82] To 
verify the suitability of the miniaturized incubator micro-
scope as a microwell for cultivation, three human cell lines 
A549 (lung), HepG2 (liver), and TH-1 (kidney) were used as 
example models for studying adhesion and cultivation, cell 
morphology (Figure  4a) as well as the percentage of viable 
and dead cells (Table 1). During cell cultivation, the platform 
is maintained at a constant temperature of 37  ±  0.5  °C. All 
studied cell types successfully adhere on the silicon nitride 
membrane and proliferate. Cells cultivated on the plat-
form show no differences in morphology, migration, adher-
ence or proliferation rate compared with cultivation under 
static conditions. A549 and TH-1 cells are characterized by 
a spindle-shaped morphology and HepG2 by a round shape 
morphology. The results of cell viability assessment using 
FDA/PI (fluorescein diacetate/propidium iodide) staining are 
comparable under microfluidic and static conditions, for all 
three tested cell types (Table 1).
After adhering to the surface of the silicon nitride mem-
brane, the cells form a dense cell layer and, depending on 
cell type, specific cell junctions (tight junctions) are formed. 
This cellular changes can be quantified noninvasively via 
impedance measurement using the gold electrodes posi-
tioned in the upper and lower fluidic channel. From the time 
of seeding, TH-1 cells proliferate in the cartridge as seen by 
an impedance change of 1061  Ω after 12  h and 1275  Ω after 
48 h (Figure 4b). In the case of the A549 cells, the impedance 
change is 1552 Ω after 12 h and 1625 Ω after 48 h. Although, 
HepG2 cells appear to proliferate more slowly in the car-
tridge, as seen by an impedance change of 710  Ω after 48  h 
(Figure  4c), they still continue to grow and proliferate. For 
instance, after 5 d (120  h) HepG2 cells show an impedance 
change of 990 Ω (Figure 4c).
2.3.2. DNA Stability of Cells under Microfluidic Conditions
HepG2 cells were cultured in the closed cartridge under flu-
idic conditions before being subjected to the enzyme-linked 
version of the comet assay for analyzing DNA stability (DNA 
strand breaks and oxidized base lesions) (Table  2). Previous 
live/dead staining (data not shown) confirms that their cell 
viability was high enough for the cells to be used for the 
comet assay (Figure  2). The basal DNA damage of HepG2 
cells in the microfluidic system is slightly higher than for the 
case where cells were cultured in standard static 2D systems 
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(96-well plate).[83] Fluidic conditions induce a slight, nonsig-
nificant increase in DNA strand breaks (SBs) but no increase 
in oxidized DNA base lesions (formamidopyrimidine Fpg) 
(Table  2). The positive control (H2O2 for DNA SBs and Fpg 
for oxidized base lesions) induce DNA damage as expected 
(Table 2).
Table 1. Proportion of viable and dead cells after 24  h cultured under 
static and fluidic conditions. Human cell lines (A549, HepG2, and TH-1) 
were cultured under standard static conditions (T25 flask, incubator, 
37 °C, 95% humidity, 5% CO2) and in the developed cartridge under flu-
idic conditions (medium flow 100 µL h−1, 37 °C). After 24 h in culture the 
viability of the cells was analyzed via live/dead staining.
Cell line Culture condition Amount of cells [%]
Viable Dead
A549 Static 97.0 ± 1.0 3.0 ± 2.5
A549 Fluidic 95.7 ± 3.3 4.3 ± 3.3
HepG2 Static 92.0 ± 2.6 8.0 ± 1.6
HepG2 Fluidic 96.0 ± 4.9 4.0 ± 2.9
TH-1 Static 95.7 ± 1.2 4.3 ± 1.0
TH-1 Fluidic 94.0 ± 3.6 6.0 ± 3.6
Table 2. Comet assay results of HepG2 cells cultured under static and 
fluidic conditions. The cells were exposed to fresh medium under static 
(96-well plate) and fluidic conditions (medium flow 100  µL  h−1, 37  °C) 
for 24  h before measurement of DNA damage via comet assay. H2O2 
(100  ×  10−6 m) was used as a positive control for DNA strand breaks 
(DNA SB). Results show mean ± standard deviation of three inde-
pendent experiments. No net Fpg was determined after H2O2 exposure.
DNA damage Culture condition % DNA in tail
Cell medium H2O2
DNA SBs Static 5.0 ± 2.3a),b) 95.5 ± 0.2c)
DNA SBs Fluidic 10.3 ± 5.2 83.3 ± 9.0
Net Fpg Static 3.7 ± 2.1a),b) –
Net Fpg Fluidic 11.6 ± 10.7 –
a)Elje et al.[83]; b)n = 9; c)Elje et al.[84]
Figure 4. Growth behavior of the human cells lines on the miniaturized incubator microscope platform. a) Bright-field imaging of different cell types 
with different morphologies, cultured under static and fluidic conditions. Human epithelium of lung (A549), liver (HepG2), and kidney (TH-1) were 
cultured under standard static conditions (T25 flask) and in the developed cartridge under fluidic conditions (medium flow 100 µL h−1). After 24 h the 
statically cultured cells were imaged via standard microscope (IX81, Olympus) and the cells in the cartridge via miniaturized incubator microscope. 
No morphological differences were identified between cells cultivated under static compared to fluidic culture conditions. b,c) Impedance analysis of 
different epithelial cell lines during their culture in the microfluidic cartridge. The human cell lines b) TH-1 and A549 and c) HepG2 were cultured in 
the developed cartridge under fluidic conditions (medium flow 100 µL h−1). Impedance analysis at 10 kHz frequency was performed in line with the cell 
cultivation over a period of b) 48 h in case of TH-1 and A549 and c) 120 h in case of HepG2. For all cell types cell proliferation resulted in an increase 
of the impedance.
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2.3.3. Validation with Reference Chemicals under Microfluidic 
Conditions
Before the platform was used for in vitro studies with nanoma-
terials, the system was validated with reference chemicals. For 
this purpose A549 cells (2 × 106 mL−1), cultured in the microflu-
idic platform, were exposed to cis-Platin (cis-Pt, 20 µg mL−1), a 
cytostatic drug whose effect is based on the inhibition of DNA 
replication by crosslinking of two adjacent guanine bases of a 
DNA strand. Impedance measurements during the cultivation 
of A549 cells in the cartridge show a significant decrease of the 
impedance after 48 h exposure to cis-Pt (Figure 5a, blue line), in 
contrast to the nonexposed cells (Figure 5a, black line). Over a 
period of 2.5 h the impedance is decreased from 1404 to 550 Ω 
(39.2%) (Figure  5a, blue line). Whereby the nonexposed con-
trol remains stable between 1568 Ω (start of the measurement) 
and 1745  Ω (2.5  h) (Figure  5a, black line). Also in the case of 
Triton X-100 (positive control), the impedance of the cells 
decreases significantly compared to the control (Figure  5a, 
green line). The value of Triton X is reduced over this period 
(2.5 h) by 100% from 1463 to 0 Ω.
EC50 value (half-maximal effective concentration) for cis-Pt 
(24 h) in A549 cells is determined to be 25 µg mL−1 under static 
conditions (data not shown). Under fluidic conditions cis-Pt 
induces the same effect as determined under static conditions 
(Figure 5b).
2.3.4. In Vitro Effect of SiO2-FITC-NP under Microfluidic 
Conditions
TH-1 cells (2 × 106  mL−1), cultured in the microfluidic plat-
form, were exposed to silica–FITC core labeled nanoparti-
cles (SiO2-FITC-NP, 100  µg  mL−1). Impedance measurements 
during the cultivation of TH-1 cells in the cartridge show 
no significant decrease in impedance after the exposure to 
SiO2-FITC-NP at 24  h (Figure  5c, red line), compared to non-
exposed cells (Figure  5c, black line). Cytotoxicity studies with 
SiO2-FITC-NP under static conditions demonstrate no toxic 
effects up to a concentration of 15.3 × 10−3 m (922 µg mL−1) over 
a duration of 24 h (data not shown). Under fluidic conditions, 
SiO2-FITC-NP induces the same effect as determined under 
static conditions (Figure 5d).
2.3.5. In Vitro Effect of SiO2-FITC-NP on the Microfluidic In Vitro 
Platform
A performance test for hazard screening via the intercon-
nected microfluidic in vitro platform (Figure  6a) was per-
formed with SiO2–FITC-NP. HepG2 cells and TH-1 cells were 
cultured in individual microfluidic cartridges (module  1 and 
module  2), interconnected via microfluidics, simulating in 
vivo-like physiology (Figure 6b). SiO2–FITC-NP were injected 
Figure 5. In vitro effects of reference chemicals and SiO2–FITC-NP under microfluidic conditions. a) Impedance analysis of A549 cells at 10 kHz fre-
quency during exposure to cis-Pt (concentration 20 µg mL−1, blue line) in the microfluidic cartridge (flow rate 100 µL h−1). Nonexposed cells (black) 
and Triton X exposed cells (green) act as negative and positive controls, respectively. b) Impedance change after 48 h exposure of A549 cells with cis-Pt, 
Triton X, and cell culture medium (control). c) Impedance analysis at 10 kHz frequency of TH-1 cells during their exposure to SiO2–FITC-NP (100 µg mL−1) 
in the microfluidic cartridge (flow rate 100 µL h−1). Nonexposed cells (black) act as negative control (control). d) Impedance change after 48 h exposure 
of TH-1 cells with SiO2–FITC-NP and cell culture medium (control).
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in module  1 (HepG2 cells) and electrical impedance meas-
urements were performed in both modules (Figure 6c). After 
the addition of SiO2–FITC-NP in module 1, the impedance of 
the HepG2 cells increase constantly due to cell proliferation, 
which does not indicate any cytotoxic effect on the HepG2 
cells. 12  h after the addition of SiO2–FITC-NP, the imped-
ance in module 2 (TH-1 cells) decreased, indicating the induc-
tion of a cytotoxic effect in the TH-1 cells (Figure  6c). The 
results indicate that the SiO2–FITC-NP were transported from 
module 1 to module 2 and the effect was cell type-dependent. 
It is also possible that the liver cells that interact first with the 
SiO2–FITC-NPs release a messenger substance, for example 
cytokines, which are transported to module 2, triggering 
a cytotoxic effect in the TH-1 cells. After demonstrating the 
detection of dose-dependent, organ-specific effects, with refer-
ence chemicals and NPs, the qualification of the system for 
transport studies was studied.
2.3.6. Transport of Au-NP over Bronchial Epithelial Cell Barrier 
under Microfluidic Conditions
The microholes in the silicon nitride membrane enable 
the transport of NPs through the membrane to the bottom 
channel. This brings the following advantages: a) transfer of the 
NPs to a second sensing module by interconnecting; b) realiza-
tion of transport studies with NPs, but also drugs and chemi-
cals; and c) sampling of transported NPs for physicochemical 
characterization. The impedance data give information on the 
coverage of the microholes by the cells and the condition of the 
cells in case of NP exposure.
The transport of Au-PEG-NP over a cell barrier was studied 
in the human bronchial epithelial cell line, 16HBE, which was 
cultured under both static and fluidic conditions. It is well 
known that 16HBE cells form tight junctions and produce a 
dense, cellular barrier in cell culture inserts. TEER serves as an 
Figure 6. In vitro effects of SiO2–FITC-NP under microfluidic conditions in the interconnected platform. a) Two interconnected microfluidic platforms. 
Right module with lid removed to show the microfluidic cartridge. b) Schematic illustration of the fluidics interconnection. c) Impedance analysis 
of HepG2 cells (module  1, black line) and TH-1 cells (module  2, red line) at 10  kHz frequency during exposure to SiO2–FITC-NP (concentration 
100 µg mL−1) on the two interconnected microfluidic platforms (flow rate 100 µL h−1). The diagram displays the impedance over time of exposure.
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indicator for the formation of tight junctions and the density of 
this cellular barrier.[69,85] After 4 d of cultivation in a 24-well cell 
culture insert, the TEER of 16HBE reaches a constant value of 
688 ± 22 Ω. This is consistent with data from other studies.[85] 
In the microfluidic system the impedance value was also con-
stant before cell exposure was started.
After exposure of 4, 24, and 48 h the amount of Au was ana-
lyzed by induced coupled plasma-mass spectroscopy (ICP-MS) 
and atomic spectroscopy. The analysis of elemental gold after 
static exposure in cell culture insert shows that even after 
48  h most of the particles remain still on the apical side of 
the 16HBE cellular barrier. The NP concentration is reduced 
over time. However, the amount of Au on the basolateral side 
was still below the detection limit after 48 h (Table 3). In the 
cell lysate, only a small increase in the amount of Au could 
be detected (0.41  ±  0.03  µg after 48  h exposure of 5  µg  mL−1 
Au-PEG-NP). Under fluidic conditions, 16HBE were exposed 
with Au-PEG-NPs (5 µg mL−1) (flow rate of 100 µL h−1, n = 2). 
As in the static setup, a time-dependent reduction of the Au 
amount in the apical medium could be detected (3.76 ± 0.26 µg 
L−1 after 4 h, 3.06 ±  0.02 µg L−1 after 24 h, 2.58 ±  0.25 µg L−1 
after 48 h). Thus, the uptake of Au-PEG-NP into the cells could 
be shown under static and fluidic conditions, which proves 
that the developed microfluidic cartridge is suitable for uptake 
and transport studies.
The presented results show that the developed microfluidic 
platform can be used for several applications in the field of 
drug testing and (nano)toxicity testing. Standard assays, which 
are commonly performed under static conditions in multiwell 
plates, were successfully modified and adapted to the dynamic 
conditions of the microfluidic platform. The use of the micro-
fluidic platform is independent of the chosen cell line. Direct 
control of the cells cultivated in the microfluidic cartridge 
was obtained by real-time imaging and real-time impedance 
measurements.
Most other approaches either do not provide real-time 
imaging of cells or require the use of a lab incubator to cul-
tivate the cells in the microfluidic devices.[86–88] The micro-
fluidic platform provides both the necessary environment for 
cell cultivation and the components for real-time electrical and 
optical detection of the cell’s growth status. Thus, the platform 
does not require any additional microscope or lab incubator. It 
meets the need for flexible technologies in the field of organ-
on-chip devices.[89,90]
The innovative flexibility of the microfluidic platform was 
shown to enable real-time investigations at the single and 
multicellular level, to study different endpoints, as cytotoxicity, 
genotoxicity, and toxicological pathways. This multimodular 
approach allows different aspects of one or several processes 
to be interrogated and analyzed simultaneously. The advantage 
of the developed platform is the application as a serial or par-
allel platform and freedom to select the number of platforms to 
interconnect with each other. Real-time TEER measurements of 
the formed cell layers inside the microfluidic cartridge has been 
successfully combined with real-time bright-field and fluores-
cent imaging of the cells in the individual modules. The com-
bination of fluidic systems with biosensors, such as impedance 
spectroscopy, and microphysiometry as well as physiology iden-
tification and quantification of the expression of specific cellular 
markers is the next level of lab-on-chip devices.[69,9,91] The devel-
oped microfluidic platform follows this approach. In contrast to 
other existing microphysiological systems,[86,92–94] the described 
cartridge fabrication can easily be adapted for higher numbers. 
Most components, such as the cartridge bottom and lid and 
adhesive foils for microchannels are suitable for mass fabrica-
tion and (semi)automated assembly. This aspect is important 
for increased acceptance and future use and marketing of those 
microphysiological systems beyond the research and develop-
ment area.
3. Conclusion
The goal of this study was to develop a more efficient, mod-
ular microfluidic in vitro platform for (nano)safety and (nano)
drug efficiency screening and to provide “how” and “why” 
answers for the fundamental processes of human response 
to NPs. For this purpose, an innovative modular microfluidic 
platform was developed with the capability of reliably analyzing 
bio-nano-interactions in real-time. The developed microfluidic 
in vitro platform allows bright field and fluorescent imaging 
in parallel with impedance measurements. This enables the 
determination of interwell cell distribution, investigation of 
changes in cell morphology and the detection of fluorescent 
dyes, reporter genes or cell markers. The developed microflu-
idic integration provides the infrastructure for the cultivation 
of artificial tissues on-chip under physiological conditions. The 
Table 3. Au elemental distribution of PEG-Au NPs after transport 
studies under static conditions. Via ICP-MS Au elemental distribution 
in apical cell culture medium, basolateral cell culture medium, and cell 
lysates were determined after the exposure of Au-PEG-NPs (5 µg mL−1) 
to human bronchial epithelial cells (16HBE) under static conditions in a 
Transwell setup. For each elemental part a blank (absence of cells, pres-
ence of Au-PEG-NP) and a control (presence of cells, absence of Au-
PEG-NP) were measured. The amounts of Au-PEG-NPs are expressed 
as total µg Au.
Elemental Au [µg] Exposure time
4 h 24 h 48 h
Static apical
Control <0.125a) <0.125a) <0.125a)
Blank 1.9 ± 0.0b) 1.6 ± 0.0b) 1.65 ± 0.05b)
Au-PEG-NP 2.57 ± 0.21 1.93 ± 0.12 1.63 ± 0.05
Static basolateral
Control <0.125a) <0.125a) <0.125a)
Blank 1.5 ± 0.05b) 1.5 ± 0.0b) 1.55 ± 0.0b)
Au-PEG-NP <1.2 <1.2 <1.2
Static cell lysate
Control <0.125a) <0.125a) <0.125a)
Blank 0.29 ± 0.07b) 0.17 ± 0.003b) 0.16 ± 0.005b)
Au-PEG-NP 0.32 ± 0.01 0.29 ± 0.03 0.41 ± 0.03
a)Controls were below the detection limit; b)In the case of the blanks, levels of Au 
around 0.165 µg were systematically measured, which are indicative enough of the 
presence of Au in the samples.
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interconnection of the different modules aims at the simulation 
of whole-body exposure and response. The platform is cell-type 
independent and can flexibly be interconnected as a serial or 
parallel system. Due to the array structure of the microholes on 
the microfabricated transparent membrane the system could 
also be used for studies on a single cell level.[95]
After successful validation with a variety of cell lines, future 
steps in development of this infrastructure include combina-
tion with other cell models, such as human induced pluripo-
tent stem cells or reporter cells, for example. The modular 
platform allows the generation of a more reliable cell-based 
assay data for many types of applications, such as safety 
analysis (endpoint and toxicokinetic studies) including food 
allergy studies, disease modeling, immune therapy develop-
ment, functional food development, and drug efficacy testing 
in the pharma area.
In all fields of application this in vitro platform contributes to 
the replacement of animal testing in risk assessment studies in 
compliance with the 3Rs to replace, reduce, and refine animal 
experiments. By simulating the in vivo-like physiological con-
ditions the microfluidic in vitro platform meets the need for 
new perspectives on in vivo-like and animal-free approaches for 
chemical and pharmaceutical safety assessment.
4. Experimental Section
Fluid Dynamics Simulation: CFD simulations of fluid flow at a flow 
rate of 100  µL  h−1 and species transport through the microfluidic 
channel, using the methodology applied to study flow through 
a similar microfluidic geometry by the authors,[96] confirmed no 
undesirable flow characteristics were observed in the microfluidic 
channel and cell cavity. The concentration of species within the cavity 
reached that of the inflow concentration after approximately 700  s, a 
short time compared to the overall timescale of the exposure period 
(24  h) during an experiment. CFD simulations were completed using 
COMSOL Multiphysics v5.3a to predict fluid flow and chemical species 
transport within the microfluidic cell. The Navier–Stokes equations 
for incompressible, steady-state, isoviscous fluid flow through the 
microfluidic channel with no gravity effects were solved
· 0u∇ =  (1)
ρ µ( )∇ = − ∇ + ∇· 2pu u u  (2)
where u is the fluid velocity vector (m s−1), p is the pressure (Pa), μ is 
the dynamic viscosity (Pa s), and ρ is the pressure (kg m−3).
Time-dependent species transport through the microfluidic channel 
was solved using the advection-diffusion transport equation
·2c
t
D c cu∂∂ = ∇ − ∇
 (3)
where c is the species concentration (mol  m−3) and D is the diffusion 
coefficient of the dilute species (m2 s−1).
The shear stress in the channel was calculated to determine if the 
fluid flow influenced the adherence of the cells to the surface of the 
microfluidic cavity. The wall shear stress was calculated along the cavity 
wall, shown in Figure 2, using the following equation
·

τ µ γ=  (4)
where τ is the shear stress (Pa), expressed as dyn  cm−2 
(1 Pa =  10 dyn cm−2), and γ  is the fluid shear rate (s−1) equivalent to 







where u is the magnitude of flow velocity (m s−1).
For 2D microfluidic channels, the wall shear stress can be estimated 
using the following expression[81]




where Q is the flow rate (m3 s–1), h is the channel height (m) and w is 
the channel width (m).
Microfluidic Cartridge: The microfluidic cartridge was designed as 
an adaptable modular device in microscope slide format. The cavity is 
fabricated by wet chemical etching of silicon in potassium hydroxide. 
The membrane has a regular array of microholes with a hole diameter 
<  5  µm that is fabricated by reactive ion etching of the silicon nitride 
layer. The cavity chip with the porous membrane is placed between 
two microfluidic channels, each having a cross section of 0.6  mm². 
The microfabricated silicon-based cavity chip was integrated into a 
microfluidic cartridge, which was made up from two injection-molded 
polystyrene plates with Luer adapters (Greiner Bio-One), a 0.5  mm 
thick ceramics plate (CoorsTek, USA) and two layers of medical grade 
pressure-sensitive adhesive (AR 90106, Adhesives Research, Ireland). The 
cartridge has a symmetrical structure with the cavity chip in the center. 
Two microchannels are defined by the adhesive layer that connects the 
polystyrene plates with the 0.5 mm thick aluminum oxide ceramics plate. 
This plate has an opening for the insertion of the silicon cavity chip and 
separates the two microchannels both electrically and fluidically. Thin film 
gold electrodes for impedance sensing were deposited by sputtering onto 
two polystyrene parts that cover two flow channels.
Miniaturized Incubator Microscope: The miniaturized microscope 
comprises two subsystems: the imaging module and the heating unit that 
is used for temperature control of the microfluidic cartridge. Based on a 
CMOS (complementary metal-oxide-semiconductor) camera, the imaging 
module was specifically designed for the microfluidic cartridge and the 
implementation into the microfluidic platform. Components with high 
accuracy requirements for the optical path were fabricated mechanically by 
computerized numeric control milling and anodized. Other components, 
including the housing for the light-emitting diode (LED) light source, 
electronics and the socket for the board-level camera, were manufactured 
by 3D-printing. The imaging module comprises a lens (Lensagon 
B10M7224, Lensation, Germany), a color CMOS camera (UI-3592LE-C, 
Image Development Systems, Germany), a fluorescence 4-band-filter-set 
for 4’,6-diamidin-2-phenylindol, FITC, tetramethylrhodamine, and Cy5 
(Semrock, USA) as well as the LEDs. An LED in the amber range (588 nm, 
LUXEON Z LXZ1-PL01, LUMILEDS, USA) was used as a light source for 
transmission bright-field imaging. Fluorescence imaging was realized 
with Köhler incident light illumination using four LEDs (LUXEON UV U 
Line, LUMILEDS, USA) with excitation wavelengths in the UV (385 nm), 
blue (470  nm), and lime range (567.5  nm), which were mounted on 
a metal core printed circuit board and controlled by multi-LED driver 
electronics. A LabView program was developed for the optical monitoring 
and analysis of cells in the microcavity. The software controls all LEDs 
and the CMOS camera, thus allowing for video recording and time-lapse 
imaging in bright-field and fluorescence mode.
All components for temperature control, together with bright-field 
illumination, were integrated into the lid of the microscope. Two Peltier 
elements, each equipped with a heat sink, are in thermal contact with 
the top part of the microfluidic cartridge, and an negative temperature 
coefficient-temperature-sensor measures the temperature at the surface 
of the microfluidic cartridge. A commercial Peltier-controller (TLK 33, Sika 
GmbH, Germany) evaluates the signals from the temperature sensor 
and controls direction and intensity of the current through the Peltier 
elements. Temperature during cultivation was measured in a test cartridge 
with an integrated Pt-100 temperature sensor. During cell cultivation 
the temperature was maintained at a value of 37  ±  0.5  °C. Stability of 
pH (between 7.4  and 7.8) and sufficient oxygen concentration in the 
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cartridge were also measured in the test setup. Samples taken from the 
microchannels at different timepoints were analyzed with a Portamess pH 
meter and oxygen concentration was measured using oxygen nanoprobes 
and a fiber-optic oxygen sensor from PyroScience (Germany).
Fluidic Circuit: Commercially available fluidic and microfluidic components 
were selected to guarantee a maximum flexibility for the platform operation. 
These commercial components comprise solenoid pinch valves (Bio-
Chem Valves, USA), syringe pumps (New Era Pump Systems, USA), and 
special microfluidic lids for Falcon tubes (Elvesys, France), which can be 
used with standard high-pressure liquid chromatography connectors and 
polytetrafluoroethylene tubing. Elastic tubing (C-Flex, Cole-Parmer, USA) 
was used in combination with the pinch valves.
Electrical Impedance Measurement: A commercial impedance analyzer 
(HP4248A) in combination with an electrical switch (Keithley 7001 switch 
system) was used for measuring the electrical impedance spectrum 
between both electrodes of the microfluidic cartridge in the range 
between 100 Hz and 100  kHz. Electrical connection of the microfluidic 
module with the impedance measuring system was carried out by 
commercial connectors that were soldered onto the contact pads of the 
cartridge. A LabView program controls data acquisition and impedance 
data were recorded in time intervals of 10 min.
System Integration of the Microfluidic Platform: All subsystems 
described form one module of the microfluidic platform. The miniaturized 
incubator microscope with the microfluidic cartridge was integrated 
with the fluidic circuit and connected to the impedance measurement 
system. The flexible modular platform concept allows for the individual 
operation of one single module and for the interconnection of multiple 
modules (Figure 6). Control of the microfluidic module was performed 
by a custom made electronic instrumentation. It provides a universal 
serial bus (USB) communication interface to support microfluidic valves 
handling by corresponding graphical user interface (GUI) software.
Reagents for Nanoparticle Synthesis: Silver nitrate (AgNO3), Gold(III) 
chloride trihydrate (HAuCl4·3H2O, 99%), trisodium citrate (Na3C6H5O7), 
and tannic acid (C76H52O46), poly(ethylene glycol) methyl ether thiol 
(mol wt 5000), tetraethyl orthosilicate (TEOS, ≥ 98%), 3-(aminopropyl)
triethoxysilane (APTES, ≥  98%), fluorescein 5(6)-isothiocyanate (FITC, 
≥  90%), hydrochloric acid ACS reagent (HCl, 37%), sodium hydroxide 
BioXtra, ≥  98% (acidimetric) pellets (anhydrous), tetramethyl-
ammonium hydroxide (TMAOH) solution ACS reagent with a 
concentration 1.0  ±  0.02  m in water and cis-diammineplatinum(II) 
dichloride, were purchased from Sigma-Aldrich. Ammonia solution 
(ACS Reagent, p.a. 28–30%) and dried ethanol (seccoSolv max 0.01% 
H2O) were purchased from Merck and titanium(IV) isopropoxide 97%, 
was purchased from Fluka Chemika. Triton X-100 was purchased from 
Applichem, FDA and PI from Invitrogen. All chemicals were used as 
received without further purification. Distilled water passed through 
a Millipore system (ρ  = 18.2  MΩ) was used in all experiments. All 
glassware was first rinsed with acetone and then with Millipore water 
before use.
Synthesis of Silver Nanoparticles (Ag-NP): Silver nanoparticles of 
≈20  nm in diameter were prepared by the seeded-growth method 
recently reported by Bastús  et  al.[97] In a typical experiment, 100  mL 
volume of an aqueous solution containing sodium citrate (SC, 5 × 10−3 
m) and tannic acid (TA, 0.1  × 10−3 m) was prepared and heated up to 
100 °C with a heating mantle in a three-neck round-bottomed flask for 
15  min under vigorous stirring. A condenser was used to prevent the 
evaporation of the solvent. After boiling had commenced, AgNO3 (1 mL, 
25  × 10−3 m) of was injected into this solution. The solution became 
bright yellow immediately indication the formation of the silver seeds. 
Immediately after the synthesis of Ag seeds and in the same vessel, 
the synthesized silver seeds were grown by cooling down the solution 
to 90 °C, the seed solution was diluted by extracting 20 mL of sample 
and adding Milli-Q-water (17  mL) and then SC (500  µL, 25  × 10−3 m), 
TA (1.5  mL, 2.5  × 10−3 m), and AgNO3 (1  mL, 25  × 10−3 m) were 
sequentially injected, again. This process was repeated up to two times, 
progressively growing the size of the Ag-NP until reaching the desired 
size ≈ 20 nm (≈ 1.8 × 1012 NP mL−1). The obtained Ag-NP were purified 
by centrifugation and stored in a solution containing both TA and SC.
Synthesis of Silica Dioxide –FITC Core Labeled Nanoparticles (SiO2-
FITC NP): Core labeled silica nanoparticles with the fluorophore FITC 
were prepared by following and adapting the method reported by van 
Blaaderen  et  al.[98] First, the silane-dye precursor was prepared. For 
this purpose, in a 100 mL flask, the FITC was measured accurately and 
dissolved in dry ethanol (50  mL). Then, the APTES was added under 
stirring and the flask was sealed using septum and left for 15 min under 
an argon atmosphere in dark conditions. Finally, the reaction was left 
for 24 h under magnetic agitation. Once the precursor was prepared, in 
a flask sealed with the help of a septum and under argon atmosphere, 
dry ethanol (45 mL) was added. Then, after 10 min of stirring, 2.02 mL 
(50.7 mmol) of ammonium hydroxide 28% was added and left for 5 min 
with continuous stirring. Finally, TEOS (1.7 mL, 7.6 mmol) and APTES-
FITC precursor (5 mL) were sequentially added in the ethanol anhydride 
solution whilst maintaining a constant solvent volume. The reaction 
was left for 24 h stirring in dark conditions. Dialysis was used to purify 
unreacted dye and precursor. All the above experiments were conducted 
at room temperature.
Synthesis of Titanium Dioxide Nanoparticles (TiO2-NP): Titanium 
anatase nanoparticles of mean size ≈ 4 nm in diameter were prepared by 
a precipitation method following and adapting the method reported by 
Pottier et al.[99] The adapted method is described in Elje et al.[83] Samples 
were further purified by three centrifuging cycles and resuspended in 
an aqueous solution of Tetramethylammonium hydroxide (TMAOH, 
100  mol  L−1). Afterwards they were characterized by transmission 
electron microscopy (TEM), dynamic light scattering, and UV–vis 
spectroscopy. The former was used to determine the particle size and to 
characterize the crystallinity of particles.
Synthesis of Polyethylene Glycol-Coated Gold Nanoparticles 
(Au-PEG-NP): Gold nanoparticles of ≈10  nm in diameter were 
prepared by the citrated-stabilized seeded-growth method reported by 
Bastús et al.[100] A solution of 2.2 × 10−3 m sodium citrate in Milli-Q water 
(150  mL) was heated with a heating mantle in a 250  mL three-necked 
round-bottomed flask for 15  min under vigorous stirring. A condenser 
was utilized to prevent the evaporation of the solvent. After boiling had 
commenced, 1  mL of HAuCl4 (25  × 10−3 m) was injected. The color of 
the solution changed from yellow to bluish-grey and then to soft pink in 
10 min. The resulting particles (≈10 nm, ≈3 × 1012 NPs mL−1) are coated 
with negatively charged citrate ions and hence are well suspended in 
H2O. Immediately after the synthesis of the Au seeds and in the same 
reaction vessel, the reaction was cooled and NPs were conjugated 
directly with a thiol-PEG MW5000 solution to a final concentration of 
2  × 10−6 m and was left overnight with gently stirring, to assure the 
complete coating of the Au NPs. Finally, the obtained PEGylated Au-NP 
were purified by centrifugation and dispersed in water, to remove the 
unbound PEG and the free citrate molecules.
UV–vis Spectroscopy: UV–visible spectra were acquired with an Agilent 
Cary 60 UV–vis spectrophotometer as described in Elje et al.[83]
Transmission Electron Microscopy: TEM diameter of the synthesized 
nanoparticles was obtained from the analysis of TEM images (Figure 3) 
acquired with an FEI Tecnai G2 F20 S-TWIN HR(S) TEM equipped with 
energy-dispersive X-ray spectroscopy detector, operated at an accelerated 
voltage of 200  kV. Microliters of the samples were prepared by drop-
casting 10  µL of the sample on a carbon-coated copper TEM grid and 
left to dry at room temperature. Scanning electron microscopy (SEM) 
was conducted using an FEI Magellan 400L XHR SEM, in scanning mode 
operated at 1 kV and in transmission mode operated at 20 kV. Scanning 
transmission electron microscopy was used for bigger sizes. Average size 
and size distribution of the samples were measured using ImageJ software 
by counting at least 300 particles from different regions of the grid.
Dynamic Light Scattering: Dynamic light scattering and laser Doppler 
anemometry were used to determine the hydrodynamic size and the 
surface charge of the nanoparticles as reported by Elje et al.[83]
Induced Coupled Plasma-Mass Spectroscopy: ICP-MS was performed 
using an ICP-MS Perkin Elmer (model: NexION 300). For ICP-MS 
analysis, the nanoparticles were dissolved in concentrated aqua regia, 
which was then heated to ensure complete dissolution of all the metals 
and diluted to an optimal concentration for ICP-MS analysis. The 
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samples for ICP-MS measurements were prepared as follows: First, 
the colloidal solution containing the nanoparticles was centrifuged at 
40.000 g for 45 min. The supernatant and the pellet were then analyzed 
separately.
Cell Lines and Standard Cell Cultivation: All cell culture reagents 
were obtained from Invitrogen (Karlsruhe, Germany), unless stated 
otherwise. The human lung epithelial carcinoma cells A549 (ATCC CCL-
185), the human lung bronchial epithelial cells 16HBE (SCC150, Merck, 
Darmstadt, Germany) and the human hepatocarcinoma cells HepG2 
(ATCC HB-8065) were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with l-glutamine (4  × 10−3 m), penicillin 
(100 U mL−1), streptomycin (100 µg mL−1), and 10% (v/v) fetal calf serum 
(FCS), as previously described in Kohl et al.[82] The human renal proximal 
tubule epithelial (TH-1) cells obtained from Kerafast were cultivated 
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
penicillin (100  U  mL−1), streptomycin (100  µg  mL−1), and 10% FCS as 
described in Sramkova et al.[101] In cocultivation experiments TH-1 cells 
were cultured in RPMI 1640 medium as all other cell lines. Cells were 
maintained in a 5% CO2 humidified atmosphere at 37 °C.
Cell Cultivation and NP Exposure in a Single Microfluidic Platform 
Module: The cells were trypsinized and diluted in cell culture medium to 
2 × 106 cells mL−1. The cell solution was manually delivered into the cavity 
of the microincubator by a syringe. After 2 h of adherence, the tubing of 
the syringe pump was connected to the microfluidic incubator module 
and fresh cell culture medium was constantly pumped through the micro 
incubator at a flow rate of 100 µL h−1. After 24 h of cultivation the cells were 
treated with the test substances. 24 h exposures with cis-Pt, SiO2-FITC-NP 
and Ag-NP were performed with this experimental setup.
Cell Cultivation and NP Exposure in Interconnected Microfluidic Platform 
Modules: Two single modules were combined using one tubing system. 
The cells were prepared as described above. Just before cell exposure 
the medium syringe of module 1 was replaced by a syringe with the test 
substance (20  µg  mL−1 cis-Pt or 100  µg  mL−1 SiO2-FITC-NP) and the 
microfluidics of the two models guaranteed a constant flow of the test 
substance in both modules. 24 h exposures with cis-Pt and SiO2-FITC-NP 
were performed with this experimental setup.
Electrochemical Cell Characterization (Impedance Measurement): 
Impedance spectra were recorded at different frequencies between 
100  Hz and 10  kHz in order to characterize barrier integrity during 
treatment with test substances. Impedance values were measured every 
10  min. Based on previous findings with microhole array membranes, 
10  kHz was selected as an appropriate measurement frequency 
Kurz et al.[102]
Live/Dead Staining: The cells were stained with FDA and PI to allow 
for visualization of live and dead cells, respectively. The cells were 
incubated in the cartridge with FDA (30 µg mL−1) and PI (40 µg mL−1) for 
up to 1 min, before washing with phosphate buffered saline (PBS) and 
imaging via the miniaturized microscope. The recorded fluorescence 
images were visually analyzed using GIMP.
Comet Assay after Experiments in Cartridge: After live/dead staining at 
the end of the culture period, cells from the microfluidic cartridge were 
detached by trypsinization (0.25%) for 10 min. The cells were resuspended 
in culture medium and centrifuged (5 min, 200 g, 21 °C), before the cell 
number was counted in Countess (Invitrogen) with trypan-blue staining, 
and the DNA damage was measured by the comet assay.
The miniaturized 12-gel modified comet assay was performed as 
described by El Yamani  et  al.,[103] with the bacterial repair enzyme 
formamidopyrimidine DNA glycosylase (Fpg, gift from Professor Andrew 
Collins, University of Oslo, Norway), which converts oxidized (majority 
of it is 8-oxoG) or alkylated purine bases to SBs[84,103,104] for detection 
of oxidized or alkylated bases. Cell cultures were disaggregated as 
explained above. As reported by Elje  et  al.[100] the cell suspension was 
mixed in ratio 1:3 with low melting point-agarose (0.8% w/v, A9414, 
Sigma-Aldrich, 37  °C) giving a final agarose concentration of 0.6% 
w/v, and mini-gels (10 µL) were made on microscope slides precoated 
with 0.5% standard melting point agarose (05066, Sigma-Aldrich). 
The samples were submerged in lysis solution (2.5  m NaCl, 0.1  m 
ethylenediaminetetraacetic acid (EDTA), 10  × 10−3 m Tris, 10% v/v 
Triton X-100, pH 10.4) for at least 1  h. As a control for SBs, separate 
slides were submerged in 100 × 10−6 m H2O2 in PBS for 5 min at 4 °C, 
washed twice for 2 min in PBS (4 °C) and then submerged in a separate 
coplin jar of lysis solution.
After lysis, slides for Fpg treatment were washed twice for 8 min in 
buffer F (40 × 10−3 m 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 0.1  m KCl, 0.5  × 10−3 m EDTA, 0.2  mg  mL−1 bovine serum 
albumin (BSA), pH 8.4), added Fpg diluted in buffer F, and covered with 
a polyethylene foil and incubated at 37 °C for 30 min in a humid box. As 
positive control for function of Fpg, reference samples were included; 
A549 cells exposed to the photosensitizer Ro 19–8022 (Hoffmann La 
Roche, Switzerland), which with light induces oxidized purines, mainly 
8-oxoG, which is detected by the Fpg.[104,105] A549 cells were exposed to 
Ro 19-8022 (2 × 10−6 m) and irradiated with visible light (30 cm distance 
from cells, 250  W) on ice for 4  min, before freezing of aliquots and 
embedding into gels on day of experiment.
After Fpg treatment, slides with cells embedded in gels were placed 
in the electrophoresis tank, submerged in electrophoresis solution 
(0.3 m NaOH, 1 × 10−3 m EDTA, pH >  13.4) for 20 min to let the DNA 
unwind, before running electrophoresis for 20  min (25  V, 1.25  V  cm−1, 
Consort EV202). The gels were neutralized in PBS, washed in ultrapure 
water and left to dry overnight. Comets were visualized after staining 
with SYBR gold (1:2000, S11494, Sigma-Aldrich), and scored in Leica 
DMI 6000 B (Leica Microsystems), equipped with an SYBRphotographic 
filter (Thermo Fischer Scientific) using the software Comet assay IV 
4.3.1 (Perceptive Instruments, Bury St Edmunds, UK). Median DNA tail 
intensity was calculated from 50 comets per gel as a measure of DNA 
SBs, with a total of three gels and 150 comets per chip sample and two 
gels and 100 comets per reference sample.
Viability Assay (alamarBlue) in 96-Well Plates: Cells were seeded at a 
density of 2 ×  104 per well into a 96-well plate and cultured for 24 h in 
cell culture medium. Exponentially growing cells were then preincubated, 
in the presence of test compounds or untreated (control) cells, for 24 h. 
After treatment, cells were incubated with 100 µL of working solution of 
alamarBlue (Invitrogen, USA) for 4  h according to the manufacturer’s 
protocol. The fluorescence (excitation 530 nm, emission 590 nm) in each 
well was measured on a microplate reader (POLARStar OPTIMA, BMG 
LABTECH). EC50 values were calculated based on the alamarBlue results.
Transport Studies under Static Conditions: 16HBE cells (8.0 × 104 per 
well) were seeded into a 12-well cell culture insert (order# 3460, 
Corning) and cultured for 4 d in cell culture medium. Via CellZScope 
the impedance was measured continuously. At an impedance value 
>  600  Ω/cm2 the cells were exposed to Au-PEG-NPs (5.0  µg  mL−1). 
After 4, 24 and 48 h the NP-containing cell culture media on the apical 
and basolateral side was removed and used for ICP MS analysis to 
determine the amount of Au in the sample. Before analysis the NPs 
were dissolved in aqua regia, which was heated to ensure complete 
dissolution of all metals. 200 µL of the cell culture media was diluted 
to a final volume of 10 mL. Cells were harvested, digested, and diluted 
to a volume of 5 mL. ICP-MS was performed using an ICP-MS Perkin 
Elmer (Model NexION 300).
Transport Studies under Fluidic Conditions: 16HBE cells (4 × 106 mL−1) 
were injected in the microfluidic cartridge and cultured for 24 h in cell 
culture medium (flow rate 100  µL  h−1). The impedance was measured 
continuously. After the impedance reached a constant value the cells 
were exposed to Au-PEG-NPs (5.0  µg  mL−1, in cell culture medium). 
During the 4 h, 24 h, and 48 h exposure the NP-containing cell culture 
media on the apical side was collected in a tube and prepared for atomic 
spectroscopy to determine the amount of Au in the sample. Before 
analysis the NPs were dissolved in pure water which was heated to 
ensure complete dissolution of all metals. Throughout the experiments 
water from NANOpure system (Wilhelm Werner GmbH, Germany) was 
used. The atomic absorption spectrometry (AAS) measurements were 
performed at 242.8 nm using a high-resolution continuum source atomic 
absorption spectrometer AA700 (Analytik Jena AG, Jena, Germany). As 
a stock solution for AAS calibration, standard 1.000  g  L−1 Au solution 
was used. The limit of detection was determined to be lower than 
0.125 µg L−1. The amount of Au in the sample was calculated as µg L−1.
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